EnBio Holdings, Inc. (6092) AI Stock Analysis

• Market Cap: ¥5.06B
• Dividend Yield: 1.46%
• Average Volume (3M): 25.91K
• Price to Earnings (P/E): 8.6
• Beta (1Y): 0.64
• Revenue Growth: 3.37%
• EPS Growth: -27.47%
• Country: JP
• Employees: 104
• Sector: Industrials
• Sector Strength: 72
• Industry: Specialty Business Services
• EPS (TTM): 66.03
• Shares Outstanding: 8,175,200
• 10 Day Avg. Volume: 21,320
• 30 Day Avg. Volume: 25,910
• PEG Ratio: -0.29
• Price to Book (P/B): 0.53
• Price to Sales (P/S): 0.45
• P/FCF Ratio: -3.37
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: ¥578.00 ▼(-6.92% Downside)

EnBio Holdings, Inc. faces significant challenges with its current stock performance. The most impactful factors are the bearish technical indicators and high valuation, which overshadow the company's strong revenue growth and operational efficiency. Addressing cash flow issues and improving profitability are crucial for enhancing the stock's attractiveness.

Positive Factors

Revenue Growth

Consistent revenue growth indicates expanding market reach and product adoption, supporting long-term business sustainability.

Operational Efficiency

Strong operational efficiency reflects effective management and cost control, enhancing long-term profitability potential.

Stable Financial Position

A balanced capital structure with reasonable leverage supports financial stability and flexibility for future growth.

Negative Factors

Profitability Challenges

Decreasing net income indicates challenges in maintaining profitability, which could impact long-term financial health.

Cash Flow Issues

Negative free cash flow due to high capital expenditures may limit the company's ability to invest in growth opportunities.

Low Return on Equity

Low ROE suggests inefficiencies in generating returns for shareholders, potentially impacting investor confidence and capital attraction.

EnBio Holdings, Inc. Business Overview & Revenue Model

Company Description

EnBio Holdings Co., Ltd. engages in soil and groundwater contamination, and renewable energy businesses in Japan. It imports and sells equipment, materials, and cleaning agents; and purchases, sells, and leases contaminated land. The company is also involved in solar power; biomass power generation; renewable energy power generation; water resource development; and ethical consumption promotion businesses. EnBio Holdings Co., Ltd. was incorporated in 1999 and is headquartered in Tokyo, Japan.

How the Company Makes Money

EnBio Holdings generates revenue through multiple streams, primarily from the sale of its biopharmaceutical products and medical devices. The company engages in direct sales to healthcare providers, hospitals, and clinics, as well as through partnerships with larger pharmaceutical companies that distribute its products. Additionally, EnBio may earn revenue from licensing agreements, where it licenses its technology or products to other firms for a fee or royalties. The company also potentially benefits from government grants and research funding, which support its R&D efforts and product development initiatives.

EnBio Holdings, Inc. Financial Statement Overview

Summary

EnBio Holdings, Inc. demonstrates strong revenue growth and operational efficiency, but faces challenges with profitability and cash flow management. The balance sheet is stable, but improvements in cash flow and profitability are needed for sustained growth.

Income Statement

EnBio Holdings, Inc. shows a robust performance with strong revenue growth of 11.44% from 2024 to 2025, indicating positive business momentum. The gross profit margin stands at 24.87% and the net profit margin at 4.24% for 2025, which are moderate but consistent over the years. However, the decline in net income from 2024 to 2025 suggests some pressure on profitability. The EBIT and EBITDA margins are healthy at 7.95% and 12.58%, respectively, reflecting efficient operational management.

Balance Sheet

The balance sheet of EnBio Holdings, Inc. reveals a solid equity base with a debt-to-equity ratio of 1.10, indicating a balanced capital structure. The return on equity (ROE) is relatively low at 4.95% for 2025, showing room for improvement in generating returns for shareholders. The equity ratio is 43.14%, suggesting a stable financial position with a reasonable level of leverage.

Cash Flow

The cash flow statement indicates challenges with free cash flow, which turned negative in 2025, driven by high capital expenditures. The operating cash flow to net income ratio is low at 0.05, highlighting potential inefficiencies in cash generation relative to net income. However, the company has maintained positive operating cash flow, which is a positive indicator of ongoing operational health.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	10.11B	10.67B	9.58B	8.12B	8.99B	6.84B
Gross Profit	2.45B	2.65B	2.48B	2.76B	2.43B	1.89B
EBITDA	668.74M	1.34B	1.62B	1.76B	1.57B	981.00M
Net Income	109.69M	452.69M	708.76M	812.06M	654.05M	304.06M
Balance Sheet
Total Assets	21.56B	21.20B	19.31B	17.35B	16.37B	15.70B
Cash, Cash Equivalents and Short-Term Investments	3.19B	3.29B	3.60B	2.83B	2.37B	2.02B
Total Debt	10.28B	10.10B	8.62B	8.90B	8.58B	9.04B
Total Liabilities	12.32B	11.96B	10.72B	10.49B	10.40B	10.38B
Stockholders Equity	9.15B	9.14B	8.49B	6.79B	5.89B	5.29B
Cash Flow
Free Cash Flow	0.00	-1.44B	584.36M	824.13M	1.25B	-1.43B
Operating Cash Flow	0.00	21.92M	1.66B	1.99B	2.41B	297.16M
Investing Cash Flow	0.00	-1.60B	-1.58B	-1.77B	-1.48B	-2.16B
Financing Cash Flow	0.00	1.27B	638.92M	240.73M	-534.92M	928.54M

EnBio Holdings, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 621.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6092, the sentiment is Positive. The current price of 621 is above the 20-day moving average (MA) of 600.50, above the 50-day MA of 590.16, and above the 200-day MA of 607.79, indicating a bullish trend. The MACD of 9.03 indicates Negative momentum. The RSI at 60.22 is Neutral, neither overbought nor oversold. The STOCH value of 78.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:6092.

EnBio Holdings, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7812	76 Outperform	¥6.32B	5.98	―	3.80%	-2.05%	27.50%
7883	71 Outperform	¥5.44B	15.45	―	2.56%	-0.82%	29.25%
3948	65 Neutral	¥7.37B	36.41	―	3.15%	-2.81%	57.37%
7850	64 Neutral	¥2.63B	8.22	―	2.24%	2.78%	16.45%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
7916	61 Neutral	¥5.21B	9.59	―	2.77%	-1.30%	―
6092	54 Neutral	¥5.06B	8.61	―	1.46%	3.37%	-27.47%

EnBio Holdings, Inc. Corporate Events

EnBio Holdings Reports Decline in Q1 2025 Financial Results

EnBio Holdings, Inc. reported a significant decline in its financial performance for the three months ended June 30, 2025, with net sales and profits showing substantial decreases compared to the previous year. The company has revised its financial forecasts for the year ending March 31, 2026, indicating a cautious outlook amidst challenging market conditions.